Company: KROS
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001104659-25-050245
Chunk: 7

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 7
---
 documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this
press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation
to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Important Additional Information and Where to Find It

On April 23, 2025, the Company filed a definitive proxy statement on
Schedule 14A (the "Proxy Statement") and form of accompanying proxy card with the SEC in connection with its 2025 Annual Meeting
and its solicitation of proxies for the Company’s director nominees and for other matters to be voted on. The Company may also file
other relevant documents with the SEC regarding its solicitation of proxies for the 2025 Annual Meeting. This communication is not a substitute
for any proxy statement or other document that the Company has filed or may file with the SEC in connection with any solicitation by the
Company. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED WITH, OR FURNISHED
TO, THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a copy of the Proxy Statement
and any amendments or supplements to the Proxy Statement and any other relevant documents filed by the Company with the SEC at no charge
at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at https://ir.kerostx.com/financials-filings/sec-filings.

Certain Information Regarding Participants

This communication is neither a solicitation of a proxy or consent
nor a substitute for any proxy statement or other filings that may be made with the SEC. The Company, its directors, its director nominees
and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies for the 2025 Annual
Meeting. Information regarding the names of such persons and their respective direct or indirect interests in the Company, by securities
holdings or otherwise, is available in the Proxy Statement, which was filed with the SEC on April 23, 2025, including in the sections
captioned "Compensation Discussion and Analysis," "Executive Compensation," "Non-Employee Director Compensation,"
"Transactions with Related Persons and Indemnification" and "Security Ownership of Certain Beneficial Owners